Equities analysts expect Agios Pharmaceuticals (NASDAQ:AGIO) to report sales of $13.02 million for the current quarter, according to Zacks. Three analysts have made estimates for Agios Pharmaceuticals’ earnings, with the highest sales estimate coming in at $14.45 million and the lowest estimate coming in at $11.10 million. Agios Pharmaceuticals reported sales of $11.35 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 14.7%. The firm is expected to issue its next earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that Agios Pharmaceuticals will report full year sales of $87.79 million for the current fiscal year, with estimates ranging from $51.60 million to $155.90 million. For the next year, analysts expect that the firm will post sales of $264.60 million per share, with estimates ranging from $81.01 million to $600.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.03). Agios Pharmaceuticals had a negative net margin of 822.32% and a negative return on equity of 61.70%. The firm had revenue of $8.80 million during the quarter, compared to analyst estimates of $11.93 million. During the same period in the previous year, the company posted ($1.56) EPS. Agios Pharmaceuticals’s revenue for the quarter was down 16.2% compared to the same quarter last year.
A number of equities research analysts recently issued reports on the company. Cann reissued a “hold” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 17th. ValuEngine upgraded Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Credit Suisse Group set a $95.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, April 11th. BidaskClub upgraded Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 3rd. Finally, SunTrust Banks set a $115.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 7th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $88.40.
In related news, insider Steven L. Hoerter sold 2,050 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $78.63, for a total transaction of $161,191.50. Following the completion of the transaction, the insider now directly owns 2,050 shares of the company’s stock, valued at approximately $161,191.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction on Monday, May 7th. The stock was sold at an average price of $81.81, for a total value of $245,430.00. Following the transaction, the insider now directly owns 2,881 shares of the company’s stock, valued at $235,694.61. The disclosure for this sale can be found here. Insiders sold a total of 62,950 shares of company stock valued at $5,102,838 over the last quarter. 3.02% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in AGIO. Lord Abbett & CO. LLC raised its position in Agios Pharmaceuticals by 175.8% during the 1st quarter. Lord Abbett & CO. LLC now owns 1,044,346 shares of the biopharmaceutical company’s stock worth $85,407,000 after purchasing an additional 665,684 shares during the last quarter. Baillie Gifford & Co. acquired a new stake in Agios Pharmaceuticals during the 1st quarter worth about $47,607,000. BlackRock Inc. grew its holdings in Agios Pharmaceuticals by 14.0% during the 1st quarter. BlackRock Inc. now owns 3,206,053 shares of the biopharmaceutical company’s stock worth $262,192,000 after acquiring an additional 393,336 shares during the period. Point72 Asset Management L.P. grew its holdings in Agios Pharmaceuticals by 343.8% during the 1st quarter. Point72 Asset Management L.P. now owns 406,090 shares of the biopharmaceutical company’s stock worth $33,210,000 after acquiring an additional 314,590 shares during the period. Finally, UBS Asset Management Americas Inc. grew its holdings in Agios Pharmaceuticals by 965.5% during the 4th quarter. UBS Asset Management Americas Inc. now owns 345,284 shares of the biopharmaceutical company’s stock worth $19,740,000 after acquiring an additional 312,878 shares during the period. 93.99% of the stock is owned by institutional investors and hedge funds.
NASDAQ:AGIO traded down $0.81 during trading hours on Friday, reaching $86.18. 118,908 shares of the company were exchanged, compared to its average volume of 528,948. The company has a market capitalization of $5.01 billion, a P/E ratio of -12.77 and a beta of 1.98. Agios Pharmaceuticals has a 1-year low of $45.96 and a 1-year high of $89.33.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.